- "Beyond PARP - Next Generation DDR
Therapeutics" scheduled for 9:00 am
on October 19th, 2016
-
VANCOUVER, Oct. 13, 2016 /CNW/ - ProNAi Therapeutics,
Inc. (NASDAQ: DNAI), a clinical-stage drug development company
advancing targeted therapeutics for the treatment of patients with
cancer, today announced that Dr. Nick
Glover, President and Chief Executive Officer, will present
an overview of the company entitled "Beyond PARP – Next Generation
DDR Therapeutics" at the 15th Annual BIO Investor Forum
in San Francisco.
The presentation is scheduled for 9:00 am
(PT) on Wednesday, October
19th, 2016. A live audio webcast and archive of
the presentation will be accessible through the ProNAi website at
www.pronai.com.
About ProNAi Therapeutics
ProNAi Therapeutics
(ProNAi) is a clinical-stage drug development company advancing
targeted therapeutics for the treatment of patients with cancer.
Our lead drug candidate, PNT737, is a highly selective, orally
bioavailable small molecule inhibitor of Checkpoint kinase 1
(Chk1), a central regulator of the DNA Damage Response (DDR)
network. In cancer cells, replication stress induced by oncogenes
(e.g. MYC and RAS) combined with loss of function in tumor
suppressors (e.g. p53 and ATM) results in persistent DNA damage and
genomic instability. Targeted inhibition of the remaining
components of the DDR network by PNT737 may be synthetically lethal
to cancer cells and have utility as a monotherapy in a range of
tumor indications. Chk1 is also believed to facilitate tumor cell
resistance to chemotherapy or radiation-induced DNA damage and the
combination of PNT737 with these standards-of-care may provide
synergistic anti-tumor activity. PNT737 is currently being
investigated in two Phase 1 clinical trials in patients with
advanced cancer.
ProNAi is also advancing PNT141, a potent, selective and orally
bioavailable small molecule inhibitor of the Cdc7 kinase undergoing
preclinical development. Cdc7 is a key regulator of both DNA
replication and the DDR network, making it a compelling emerging
target for the potential treatment of a broad range of tumor types.
As both Chk1 and Cdc7 have potentially complementary cell cycle
checkpoint and DDR functions, inhibiting both of these targets
simultaneously may be advantageous. This potential biological
synergy presents opportunities for novel proprietary combination
strategies involving PNT737 and PNT141. ProNAi retains the
global commercialization rights to both PNT737 and PNT141. For more
information, please visit www.pronai.com.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding ProNAi's anticipated clinical development and
the potential benefits of ProNAi's product candidates. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. These statements
are based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those
described in the forward-looking statements. Such forward-looking
statements are subject to risks and uncertainties, including, among
others, the risk that ProNAi may be unable to successfully develop
and commercialize product candidates, PNT737 and PNT141 are at
early stages of development and may not demonstrate safety and
efficacy or otherwise produce positive results, ProNAi may
experience delays in the preclinical and anticipated clinical
development of PNT737 or PNT141, ProNAi may be unable to acquire
additional assets to build a pipeline of additional product
candidates, ProNAi's third-party manufacturers may cause its supply
of materials to become limited or interrupted or fail to be of
satisfactory quantity or quality, ProNAi's cash resources may be
insufficient to fund its current operating plans and it may be
unable to raise additional capital when needed, ProNAi may be
unable to obtain and enforce intellectual property protection for
its technologies and product candidates and the other factors
described under the heading "Risk Factors" set forth in ProNAi's
filings with the Securities and Exchange Commission from time to
time. ProNAi undertakes no obligation to update the forward-looking
statements contained herein or to reflect events or circumstances
occurring after the date hereof, other than as may be required by
applicable law.
SOURCE ProNAi Therapeutics Inc.